Important note

This AI stock analysis for Crispr Therapeutics is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Crispr Therapeutics - AI Stock Analysis

Analysis generated May 21, 2025

CRISPR Therapeutics AG is a prominent biotechnology company specializing in the development of gene-based therapies using CRISPR/Cas9 technology. This cutting-edge technology harnesses the CRISPR-Cas9 gene-editing technology to treat genetic diseases. Despite its promising potential in the biotech industry, the company’s performance indicators have shown a mix of successes and challenges.

Fundamental Analysis

Revenue: For the last quarter, CRISPR Therapeutics reported revenue of $0, indicating a 100% decrease compared to the previous quarter and the same quarter last year. This is a significant cause for concern and underscores challenges in revenue generation.

Net Income: The company posted a net income of $136 million, which reflects a decrease of 264.49% from the prior quarter. This stark decline highlights potential operational struggles. However, compared to the same quarter last year, this amount represents a 16.64% decrease, which is still concerning but relatively less drastic.

EBITDA: The EBITDA for the last quarter was $144 million, representing a decrease of 140.50% from the previous quarter and a decrease of 5.84% from the same quarter last year. These figures indicate substantial drops in profitability on a quarter-to-quarter basis.

Additionally, insider selling over the last couple of months could be interpreted as a bearish signal, as it may indicate that insiders do not have strong confidence in the company's short-term performance.

Technical Analysis

The current stock price of CRISPR Therapeutics stands at $36.99, reflecting a short-term decrease of 2.19% compared to one month ago. Additionally, there has been a more concerning long-term decrease of 34.88% compared to a year ago.

The current Simple Moving Average over 10 days (SMA10) is 37.80, which has increased from the previous SMA10 of 37.66, indicating a potential upward trend in price movement. The Relative Strength Index (RSI) is currently at 65.4, suggesting a neutral condition where the stock is neither overbought nor oversold.

Alternative Data Analysis

Job Postings and Employee Sentiment: CRISPR Therapeutics has increased its job postings by 200% in the last couple of months, showing signs of growth and expansion. However, employee sentiment is low with only 40% of employees holding a positive outlook on the company's future, marking a concerning 13% drop in optimism in recent months.

Customer Acquisition and Engagement: The company’s website has attracted an estimated 100,000 visitors, reflecting a bullish increase of 7% in the last couple of months. While customer engagement on social media platforms like Twitter remains steady at 23,000 followers, with no significant change recently.

AltIndex AI Score: CRISPR Therapeutics has been given an AI score of 51 by AltIndex, which signals a 'hold' recommendation. This score attempts to predict the company's stock price based on combined fundamental, technical, and alternative data analysis.

Conclusion and Recommendation

Considering the mixed signals from multiple fronts — from concerning revenue and profitability trends, technical indicators showing neutrality, to alternative data suggesting both growth and employee sentiment challenges — CRISPR Therapeutics presents a complex investment case. The company shows promise in terms of technological capability and expansion potential but faces significant operational and sentiment-related challenges. Current stock price trends and AI scoring suggest a neutral stance. Therefore, a cautious 'hold' recommendation is advised until clearer indicators of sustained recovery or improvement emerge.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.